AbCellera Biologics Inc. (ABCL)
$4.7
-0.07 (-1.47%)
Rating:
Recommendation:
-
| Symbol | ABCL |
|---|---|
| Price | $4.7 |
| Beta | 0.012 |
| Volume Avg. | 2.01M |
| Market Cap | 1.360B |
| Shares () | - |
| 52 Week Range | 4.67-14.97 |
| 1y Target Est | - |
| DCF Unlevered | ABCL DCF -> | |
|---|---|---|
| DCF Levered | ABCL LDCF -> | |
| ROE | -6.05% | Neutral |
| ROA | -4.81% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 7.03% | Neutral |
| P/E | -18.08 | Strong Sell |
| P/B | 1.14 | Strong Buy |
Latest ABCL news
About
Download (Excel)AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.